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NR2F1 Mutations Cause Optic Atrophy
with Intellectual Disability
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Optic nerve atrophy and hypoplasia can be primary disorders or can result from trans-synaptic degeneration arising from cerebral
visual impairment (CVI). Here we report six individuals with CVI and/or optic nerve abnormalities, born after an uneventful preg-
nancy and delivery, who have either de novo heterozygous missense mutations in NR2F1, also known as COUP-TFI, or deletions
encompassing NR2F1. All affected individuals show mild to moderate intellectual impairment. NR2F1 encodes a nuclear receptor
protein that regulates transcription. A reporter assay showed that missense mutations in the zinc-finger DNA-binding domain
and the putative ligand-binding domain decrease NR2F1 transcriptional activity. These findings indicate that NR2F1 plays an
important role in the neurodevelopment of the visual system and that its disruption can lead to optic atrophy with intellectual
disability.Optic nerve abnormalities are increasingly recognized as a
cause of poor vision. The most frequently identified abnor-
malities consist of optic nerve atrophy or hypoplasia, due
to either genetic or acquired causes.1 Optic nerve hypopla-
sia is often reported as part of a syndrome, for example, in
conjunction with structural malformations of the brain
or hypopituitarism, as observed in SOX2-related disorders
(MIM 184429),2 or combined with anterior segmental
defects of the eye, such as iris coloboma in PAX6-related
diseases (MIM 307108).3 Optic nerve atrophy, however,
can be part of a progressive syndromic or nonsyndromic
disorder. The genetic defects underlying many syndromic
forms of optic atrophy are known, but the molecular bases
of nonsyndromic forms have been elucidated in only a few
instances: mutations in OPA1 (MIM 605290) and OPA3
(MIM 606580) (autosomal-dominant inheritance),4,5 in
TMEM126A (MIM 612988) (autosomal-recessive inheri-
tance),6 and in mitochondrial DNA as part of the Leber
Hereditary Optic Neuropathy (LHON) (MIM 535000).7
Both optic atrophy and hypoplasia can be caused by
trans-synaptic degeneration as a part of cerebral visual
impairment (CVI), a class of disorders of the projection
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The Americto two-thirds of the cases of CVI are thought to be caused
by perinatal damage, often the result of preterm birth, but
genetic defects might play a significant role in the etiology
of the remaining cases.11–13 The majority of persons with
CVI exhibit additional clinical features, including intellec-
tual disability (ID).11–14
We collected 56 individuals with CVI, all born after an
uneventful pregnancy and birth, without any identifiable
causes, and performed clinical, ophthalmological, and
copy number variant investigations (see Table S1 available
online). This study was approved by the Ethics Commit-
tee of the Radboud university medical center (Commis-
sie Mensgebonden Onderzoek, regio Arnhem-Nijmegen),
and written informed consent was obtained for all enrolled
subjects. For 12 individuals and their parents, we per-
formed exome sequencing by using a trio approach.15,16
Exome sequencing was done in ten of these trios through
the Baylor-Hopkins Center for Mendelian Genomics;
methods have been reported previously.17 In brief, 1 mg
of genomic DNA from each individual was fragmented
in a Covaris sonication system. Whole-exome targeted
capture was performed in solution with the BCM-HGSC
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HiSeq 2000 platform (Illumina), producing an average of
9–10 Gb of raw data per sample. The sequence reads were
mapped and aligned to the Human Genome Reference
Assembly GRCh37/hg19 with the BCM-HGSC Mercury
pipeline18 at an average depth of coverage of 1143. Variant
calling was performed with the Atlas219 and SAMtools20
algorithms; variant annotation was performed with an
intramurally developed annotation pipeline21 based on
ANNOVAR22 and custom scripts to incorporate multiple
databases to inform on identified variants. In the other
two trios, we performed exome sequencing on a SOLiD
5500XL platform (Life Technologies) with the Agilent
SureSelect All Exon V4 reagent for target enrichment
(Agilent Technologies). The 50 bp paired-end reads were
mapped to USCS Genome Browser GRCh37/hg19 Human
Genome Reference Assembly, and variants and indels were
called with Lifescope v2.1 (Life Technologies). There was
an average coverage of 763. After quality filtering (variant
reads >15%) and exclusion of local and global variants
(<1% occurrence), a de novo analysis was performed for
all trios. Synonymous variants with no effect on splicing
were excluded.
In two persons (individuals 1 and 2) de novo missense
mutations predicted to be pathogenic were identified in
nuclear receptor subfamily 2, group F, member 1 gene,
NR2F1 (chr5: 92921073 G>C; c.344G>C; p.Arg115Pro
and chr5: 92921068 C>A; c.339C>A; p.Ser113Arg, respec-
tively; Figure 1, Table S2) (MIM 132890, RefSeq accession
number NM_005654.4). Both were situated in the DNA-
binding domain. In addition to CVI, individual 1 had
small optic discs with large excavations and ID; individual
2 manifested pale optic discs, small optic nerves on MRI,
and developmental delay (Table 1; Table S3). We screened
the remaining 44 CVI persons for mutations in NR2F1 by
Sanger sequencing and identified a third case (individual
3) with a de novomissense mutation, predicted to be path-
ogenic, in the ligand-binding domain, chr5: 92923914
T>C; c.755T>C; p.Leu252Pro. She had excavated, pale
optic discs and ID.
The Poisson probability of identifying three de novomu-
tations by sequencing a cohort of 56 personswas calculated
forNR2F1. Based on a de novomutation rate of 1.183 108
per position23 and accounting for GC-content and gene
size,24–26 the Poisson probability is p ¼ 1.40 3 1010, indi-
cating that this is highly unlikely to have occurred by
chance. This is further strengthened by the consistent clin-
ical phenotype observed in the affected individuals.
Point mutations in NR2F1 have not yet been reported,
but large deletions spanning NR2F1 and other genes have
been associated recently with optic atrophy, visual motor
integration deficit, visual perceptual disorder, and ID.27
Therefore, we searched for deletions of NR2F1 in both
the CVI cohort and the intramural database of the Rad-
boud university medical center, Nijmegen, Netherlands,
that includes more than 10,000 array analyses from per-
sons with intellectual disability and/or multiple congen-
ital abnormalities. We identified a 5q15 deletion, arr304 The American Journal of Human Genetics 94, 303–309, February5q15(92845157–93679748)x1 (HumanGenome Reference
Assembly GRCh37/hg19) comprising NR2F1 with the
CytoScan HD array (Affymetrix) in individual 4, part of
the CVI cohort, who had pale optic discs and mild ID
(Figure 1). The inheritance of the deletion is unknown,
because the deletion was on the paternal allele, but the
reportedly phenotypically normal father was not available
for testing. We also identified a de novo deletion on chr5:
91064110–93896378 (Human Genome Reference Assem-
bly CRCh37/hg19), arr SNP 5q14.3q15(SNP_A-1810903–
>SNP_A-1788922)x1 in the intramural cohort (individual
5) with the 250k SNP array (Affymetrix). Individual 5 had
developmental delay and ophthalmological examination
showed poor visual acuity, CVI, in the right eye a small
pale optic disc, and in the left eye a pale optic disc with a
large excavation.
In parallel, a single additional individual with congenital
optic atrophy and ID was enrolled through the Baylor-
Hopkins Center forMendelian Genomics study (individual
6, BAB3468, Figure 1; Table 1). This 35-year-old female also
had autism spectrum disorder with marked obsessive-
compulsive behaviors. The pregnancy and delivery had
been uneventful (Table S1). Family history was negative
for optic nerve atrophy, ID, developmental delay, and
autism. The family was consented through a research
protocol approved by the Institutional Review Board
(IRB) of Baylor College of Medicine. DNA samples from
the proband and her unaffected parents were submitted
for exome sequencing by using a trio approach as
described above at an average depth of coverage of 1073
and with >91% of the target bases covered at a minimum
of 203. Inheritance of the identified variants was exam-
ined with the DeNovoCheck algorithm.16 Analysis of
the variants identified in the proband under a sporadic
de novo model of inheritance revealed a missense muta-
tion (chr5: 92921064 G>A; c.335G>A; p.Arg112Lys) in
NR2F1. This variant was situated in the DNA-binding
domain and was predicted to be pathogenic.
As individual 6 manifested optic nerve atrophy without
CVI, a cohort of mainly nonsyndromic persons (n ¼ 37)
with optic nerve abnormalities was screened for NR2F1
variants by Sanger sequencing (Table S4). In a 68-year-old
male with optic atrophy, a missense mutation was identi-
fied, chr5:92924068 G>C; c.909G>C; p.Gln303His. How-
ever, this variant was also present in his unaffected sister
and son and was interpreted as a nonpathogenic variant.
NR2F1 encodes a conserved orphan nuclear receptor
protein (nuclear receptor subfamily 2, group F, member
1) that, activated by a yet unknown ligand, regulates tran-
scription.28 It belongs to the nuclear receptor superfamily,
of which several members already have been implicated in
human disease: NR2E3 (MIM 604485) in retinitis pigmen-
tosa,29 ESRRB (MIM 602167) in deafness,30 NR0B1 (MIM
300473) in congenital adrenal hypoplasia,31 and NR2F2
(MIM 107773) in congenital diaphragmatic hernia.32
NR2F1 has a classic nuclear receptor structure with two
main domains, a functional DNA-binding domain (DBD)6, 2014
Figure 1. Phenotype and Genotype of the Individuals with Optic Atrophy
(A) Confirmation by Sanger sequencing of the de novo mutations in NR2F1 [NM_005654.4] found by exome sequencing (individuals 1,
2, and 6), the de novo mutation in NR2F1 found by cohort screening (individual 3), and segregation analyses. The pictures of the
individuals show nonspecific facial dysmorphisms.
(B) Schematic representation of NR2F1, containing a DNA-binding domain (DBD) and a ligand-binding domain (LBD). The positions of
the mutations identified in the affected individuals are indicated.
(C) Overview of the 5q14-q15 region encompassing the two overlapping microdeletions of individual 4 (lower red bar) and 5 (upper red
bar) comprising NR2F1. The inheritance of the deletion in individual 4 was unknown, because the father was not available for testing
and the deletion was on the paternal allele. The deletion of individual 5 was de novo. The pictures of the affected individuals show
nonspecific facial dysmorphisms.formed by two zinc-finger structural domains and a
ligand-binding domain (LBD) with two highly conserved
sequence regions.33 Interestingly, three of the four pointThe Americmutations that we identified localize to the DBD of
NR2F1, probably affecting the binding of NR2F1 to its
transcriptional targets.an Journal of Human Genetics 94, 303–309, February 6, 2014 305
Table 1. Genotype and Phenotype of the Affected Individuals
Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6
Defect in
NR2F1
c.344G>C
p.Arg115Pro
c.339C>A
p.Ser113Arg
c.755T>C
p.Leu252Pro
Deletion
(0.83 Mb)
Deletion
(2.85 Mb)
c.335G>A
p.Arg112Lys
Gender Male Female Female Female Female Female
Age 12y 2þ4y 18y 24y 4y 35 y
Development IQ 48 DD IQ 55–65 IQ 61–74 DD IQ 52
Behavioral
abnormalities
- - - - - OCD, autism
OFC (centile) 98th 55th 55th 99th 50th 13th
CVI þ þ þ þ þ -
Optic disc
abnormalities
Small and large
excavation
Pale Pale and large
excavation
Partial pale Small, pale and
large excavation
Pale
MRI brain Normal Small optic nerve
and chiasm
ND ND Normal Normal
DD, developmental delay; ND, not done; OCD, obsessive-compulsive disorder; OFC, occipital frontal head circumference.To investigate the functional effects of our identified
point mutations in NR2F1, we established a reporter assay.
In this assay, luciferase is under control of an NR2F1 acti-
vated promoter and cells are cotransfected with this
plasmid and either wild-type (WT) or mutant Nr2f1 con-
structs. The luciferase activity reflects the transcriptional
activity of the constructs. The expression plasmids of the
mouse Nr2f1 - COUP-TFI, and the NGFI-A (168/þ33)
promoter luciferase reporter in pXP2 were previously
described.34,35 All point mutations were generated with
the QuickChange site-directed mutagenesis kit (Agilent).
For luciferase assays, HEK293T cells were plated in 24-
well plates (1 3 105 cells per well) 24 hr prior to transfec-
tion. Cells were transfected with 5 ng of reporter per well
with Lipofectamine 2000 following the manufacturer’s
instructions. Forty-eight hr after transfection, cells were
harvested and luciferase activity wasmeasured by the lucif-
erase assay system (Promega). As indicated in Figure 2, all
DNA-binding domainmutants (p.Arg112Lys, p.Ser113Arg,
and p.Arg115Pro) and the ligand-binding domain mutant
(p.Leu252Pro) lost their ability to fully activate NR2F1 -
COUP-TFI reporter. This result supports our contention
that persons who have these mutations do not have fully
functional NR2F1 - COUP-TFI product.
Additionally, the function of NR2F1 has been investi-
gated in mice. The mouse ortholog, Nr2f1, is expressed
in various tissues throughout development, with impor-
tant functions in cell-fate determination, differentiation,
migration, and survival, and an apparently important
role in organogenesis.33 In the developing nervous system,
it is mainly expressed at high levels in the optic nerve, thal-
amus, and pallium (future cortex).36–38 Studies of Nr2f1
knockout mice indicate that the protein is important for
neurodevelopment, including oligodendrocyte differentia-
tion (partly in vitro experiment),36 cortical patterning,39–41
and guidance of thalamocortical axons,42 as well as eye
and optic nerve development.35,43 Furthermore, over-306 The American Journal of Human Genetics 94, 303–309, Februaryexpression of Nr2f1 in mouse neuronal differentiating
teratocarcinoma PCC7 cells antagonized neuronal differ-
entiation induced by retinoic acid signaling.44 Given our
results from the in vitro reporter assays and because dele-
tions ofNR2F1 give rise to a similar phenotype, we hypoth-
esize that the heterozygous mutations identified in our
affected individuals cause loss of function and that the
observed phenotypes are due to haploinsufficiency. Inter-
estingly, it appears that the latter are restricted to brain
and optic nerves, because no other major organ abnormal-
ities are observed in our cohort of patients with either
NR2F1 point mutations or deletions. This might be due
directly to levels of NR2F1 reduced below a threshold
necessary during brain development or indirectly via the
target genes it regulates for specific expression in brain
development. Brown et al. proposed haploinsufficiency
of NR2F1 as the cause of deafness and multiple congenital
anomalies in an individual with NR2F1 deletion and para-
centric inversion inv(5)(q15q33.2).45 The absence of deaf-
ness and multiple congenital anomalies in the affected
individuals 4 and 5 suggests that these might be caused
by the more complex chromosomal rearrangement identi-
fied in the reported person, although phenotypic vari-
ability cannot be ruled out at this time.
In addition to the optic nerve abnormalities, five out of
six individuals were diagnosed with CVI. This potentially
could reflect thalamocortical axon projection disorders,
as reported in Nr2f1 knockout mice.42 Until now, optic
atrophy in combination with optic disc excavation was
thought to be the result of perinatal damage.46–48 We
showed, however, that optic disc excavations can also be
present in individuals with a genetic cause of CVI (individ-
uals 1, 3, and 5). NR2F1 investigation should, therefore,
also be considered in preterm children with CVI.
In conclusion, four individuals with optic atrophy and
CVI of unknown cause had heterozygous de novo point
mutations in NR2F1, and two persons with a similar6, 2014
Figure 2. In Vitro Luciferase Reporter Assay forNR2F1 PointMu-
tations
Effects of the Nr2f1 (COUP-TFI) mutations on activation of an
NGFI-A promoter-driven reporter. Top shows that pXP2-NGFI-A
was cotransfected with 5 ng FLAG-tagged Nr2f1 (COUP-TFI) WT,
FLAG-tagged Nr2f1 (COUP-TFI) mutations or empty vector into
HEK293T cells as indicated. The cell sample transfected with
pXP2-NGFI-A and vector served as the control, and its value
(relative luciferase activity) was set as 1. The relative luciferase
activities of the other samples are normalized to this control.
Data are means 5 SD (n ¼ 3). Bottom shows immunoblot
analysis of Nr2f1 (COUP-TFI) expression in transfection. Results
indicate similar expression of WT and mutant Nr2f1 (COUP-TFI)
constructs.phenotype had deletions comprising NR2F1. Our findings
indicate that NR2F1 has an important role in the develop-
ment of the visual system and that haploinsuffiency can
lead to optic atrophy with intellectual impairment.Supplemental Data
Supplemental Data include four tables and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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